1. Introduction {#sec1-marinedrugs-15-00120}
===============

Marine bryozoans are important sources for the discovery of new bioactive secondary metabolites. There are three reports containing 19 new metabolites isolated from this understudied phylum in the last year alone \[[@B1-marinedrugs-15-00120]\]. Modern phytochemical and pharmacological investigations of marine bryozoans demonstrated that secondary metabolites, including macrolides, alkaloids, sterols, as well as halogen-containing compounds, etc., exhibited remarkable cytotoxic activities on tumor cell lines, such as human myeloid leukemia HL-60, human leukemia U937, murine lymphocytic leukemia P388, and so on \[[@B2-marinedrugs-15-00120],[@B3-marinedrugs-15-00120]\]. *Cryptosula pallasiana* is an encrusting colonial marine bryozoan, belonging to the class Gymnolaemata, order Cheilostomata and family Cryptosulidae. In our previous investigation on the bioactive compounds from this marine bryozoan, 16 alkaloids, 13 sterols, three aromatic compounds and two glycerol derivatives have been identified \[[@B4-marinedrugs-15-00120],[@B5-marinedrugs-15-00120],[@B6-marinedrugs-15-00120]\]. In the course of our ongoing discovery of new biologically active secondary metabolites from marine bryozoans, *C. pallasiana,* collected from the coasts of Huang Island in Qingdao City, Shandong Province of China, was investigated. We report herein the isolation and structure elucidation of three new compounds including one sterol (**1**) and two ceramides (**6** and **7**), along with six known secondary metabolites including three sterols (**2**--**4**), one lactone (**5**) and two ceramides (**8**,**9**). The structures of the known compounds were identified by comparison of their physical and spectroscopic data with those reported in the literature ([Figure 1](#marinedrugs-15-00120-f001){ref-type="fig"}). In addition, the cytotoxicity of the isolated compounds against human tumor cell lines HL-60, Hep-G2 and SGC-7901 are also described.

2. Results {#sec2-marinedrugs-15-00120}
==========

The 95% EtOH extract of *C. pallasiana* was concentrated and partitioned with petroleum ether, CCl~4~ and *n*-BuOH, respectively. The resulting CCl~4~ portion was separated by column chromatography (CC) and high-performance liquid chromatography (HPLC) to afford a new sterol (**1**) and two new ceramides (**6** and **7**), along with six known compounds (**2**--**5**, **8** and **9**) ([Figure 1](#marinedrugs-15-00120-f001){ref-type="fig"}). The known compounds were identified as cholest-5-en-3β-ol (**2**) \[[@B7-marinedrugs-15-00120]\], (22*E*)-cholesta-7,22-dien-3β,5α,6β-triol (**3**) \[[@B8-marinedrugs-15-00120]\], (24*S*,22*E*)-methylcholesta-7,22-dien-3β,5α,6β-triol (**4**) \[[@B8-marinedrugs-15-00120]\], loliolide (**5**) \[[@B9-marinedrugs-15-00120]\], (2*S*,3*R*,4*E*)-2-(tetradecanoylamino)-4-octadecen-l,3-diol (**8**) \[[@B10-marinedrugs-15-00120]\] and (2*S*,3*R*,4*E*,8*E*)-2-(hexadecanoylamino)-4,8-octadecadien-l,3-diol (**9**) \[[@B11-marinedrugs-15-00120]\], respectively, by comparison of their spectroscopic data (see [supplementary information](#app1-marinedrugs-15-00120){ref-type="app"}) with those reported in the literature.

Compound **1** was obtained as a white amorphous powder. Its molecular formula was determined as C~28~H~46~O~2~ on the basis of the positive high-resolution electrospray ionization mass spectroscopy (HRESIMS) *m/z* 437.3395 \[M + Na\]^+^ (C~28~H~46~O~2~Na, calcd. for 437.3396). The ^1^H-NMR spectrum of **1** showed two tertiary methyl resonance signals at δ~H~ 0.73, s (H~3~-18) and 1.00, s (H~3~-19), three secondary methyl groups at δ~H~ 0.95, d, *J* = 5.9 Hz (H~3~-21), δ~H~ 1.67, d, *J* = 1.0 Hz (H~3~-26) and 1.74, d, *J* = 1.1 Hz (H~3~-27), one methoxy group at δ~H~ 3.21 s (OMe-23), two oxymethine protons at δ~H~ 3.52, m, (H-3) and 3.94, dt, *J* = 9.3, 3.1 Hz (H-23), and two tri-substituted olefinic protons at δ~H~ 5.35, t, *J* = 2.5 Hz (H-6) and 5.03, td, *J* = 9.0, 2.6, 1.3 Hz (H-24). The ^13^C-NMR spectrum showed 28 carbon resonances, which were assigned by distortionless enhancement by polarization transfer (DEPT) and heteronuclear single quantum coherence (HSQC) spectra to one methoxy carbon at δ~C~ 55.7 (OMe-23), five methyl (C-18, C-19, C-21, C-26 and C-27), nine methylene sp^3^ (C-1, C-2, C-4, C-7, C-11, C-12, C-15, C-16 and C-22), seven methine sp^3^ (C-3, C-8, C-9, C-14, C-17, C-20 and C-23) including two hydroxymethines C-3 (δ~C~ 71.8) and C-23 (δ~C~ 74.8), two quaternary sp^3^ carbons (C-10 and C-13), two methine sp^2^ carbons C-6 (δ~C~ 121.7) and C-24 (δ~C~ 127.0), and two quaternary sp^2^ carbons C-5 (δ~C~ 140.7) and C-25 (δ~C~ 134.5). These data suggested that **1** possessed a 3-hydroxy ∆^5^-steroid nucleus with a methoxy group and double bond in its side chain. Further structural information for compound **1** was obtained by 2D NMR analysis including ^1^H-^1^H correlation spectroscopy (COSY) and heteronuclear multiple bond correlation (HMBC) spectra ([Figure 2](#marinedrugs-15-00120-f002){ref-type="fig"}). The observation of correlations from H-23 to H~2~-22 and H-24 in the ^1^H-^1^H COSY spectrum, and correlations from methoxy proton to C-23, from H~2~-22 to C-23, from H~3~-26 to C-24 and C-25, and from H~3~-27 to C-24 and C-25 in the HMBC spectrum indicated that the methoxy group is on C-23, and the tri-substituted double bond is between C-24 and C-25. Based on the above evidences, the planar structure of sterol **1** could be established as 23-methoxycholest-5,24-dien-3-ol.

The stereochemistry of **1** was established by extensive analysis of nuclear overhauser effect spectroscopy (NOESY) spectrum and quantum electronic circular dichroism (ECD) calculations*.* The ^1^H-NMR assignment of α and β protons for compound **1** ([Table 1](#marinedrugs-15-00120-t001){ref-type="table"}) was based on careful analysis of the NOESY spectrum as well as comparison with the reference \[[@B5-marinedrugs-15-00120]\] ([Figure 3](#marinedrugs-15-00120-f003){ref-type="fig"}). The NOESY correlations from H~3~-19 to H-1α and H-1β, from H-3 to H-4α and H-2α, and from H-4α to H-6, suggested that the A-ring exists in a chair conformation. The 3-hydroxyl group was oriented in an equatorial position and therefore in a β-orientation, which was confirmed by the chemical shift of C-3 (δ~C~ 71.8 \> 70.0) \[[@B12-marinedrugs-15-00120]\]. Similarly, the presence of a cross-peak between H-14 and H-17 implied that the C-17 side chain was in a β-position. The correlations from H~3~-21 to H-12β and H-17, and from H-20 to H-16β and H~3~-18 indicating the α-orientation of the methyl group at C-20, and determined the C-20*S* configuration for **1**. The C-23*R* configuration was determined by ECD calculations of 23*R* and 23*S* for **1** using the time-dependent density functional theory (TD-DFT) method at the B3LYP/6-31G (d) level \[[@B13-marinedrugs-15-00120],[@B14-marinedrugs-15-00120],[@B15-marinedrugs-15-00120],[@B16-marinedrugs-15-00120]\]. The preliminary conformational distribution search was performed by HyperChem 7.5 software (Hypercube, Inc., Gainesville, FL, USA). The corresponding minimum geometries were fully optimized by using DFT at the B3LYP/6-31G (d) levels implemented in the Gaussian 09 program package. The ECD calculations were performed after optimization of the selected conformers at the B3LYP/6-31G (d) \[[@B17-marinedrugs-15-00120],[@B18-marinedrugs-15-00120]\]. The result showed that the experimental circular dichroism (CD) curve of **1** was consistent with the calculated ECD curve of 23*R*, while opposite to that of 23*S* ([Figure 4](#marinedrugs-15-00120-f004){ref-type="fig"}). The NOESY correlations from H-23 to H-20, H-22α and H~3~-26, and from H-24 to H-22α, H-22β and H~3~-27, indicated the α-orientation of the methoxy group at C-23, which also confirmed the 23*R* configuration. Thus, sterol **1** was unambiguously elucidated as (23*R*)-methoxycholest-5,24-dien-3β-ol.

Compound **6** was obtained as a white amorphous powder. The (+)-HRESIMS showed a pseudomolecular ion peak at *m/z* 530.4545 \[M + Na\]^+^ (calcd. for C~32~H~61~NO~3~Na, 530.4549), which, together with the pseudomolecular ion peak at *m/z* 506 \[M − H\]^−^ in the (‒)-ESIMS spectrum, enabled the determination of the molecular formula for **6** as C~32~H~61~NO~3~. A careful analysis of the ^1^H- and ^13^C-NMR spectra of **6** ([Table 2](#marinedrugs-15-00120-t002){ref-type="table"}) by DEPT and HSQC experiments revealed the presence of an amide group δ~C~ 174.0 (C-1′), δ~H~ 6.25, d, *J* = 7.5 Hz (NH), a nitrogen- or oxygen-bearing methine δ~C~ 54.5 (C-2), δ~H~ 3.95, dd, *J* = 11.3, 3.5 Hz (H-2), an oxymethylene sp^3^ δ~C~ 62.5 (C-1), δ~H~ 3.70, dd, *J* = 11.3, 3.3 Hz and 3.90, m (H~2~-1), an oxymethine sp^3^ δ~C~ 74.7 (C-3), δ~H~ 4.32, *m* (H-3), and four methine sp^2^ δ~C~ 129.2 (C-4), δ~H~ 5.54, dd, *J* = 15.4, 6.4 Hz (H-4); δ~C~ 133.6 (C-5), δ~H~ 5.78, dt, *J* = 15.4, 6.6 Hz (H-5); δ~C~ 131.4 (C-8), δ~H~ 5.42, dt, *J* = 15.2, 6.3 Hz (H-8) and δ~C~ 129.0 (C-9), δ~H~ 5.37, dt, *J* = 15.2, 6.4 Hz (H-9), which together with a series of alkyl proton signals (δ~C~ 29.2--29.7, δ~H~ 1.26, *br s*), indicated an existence of a sphinga-4,8-diene skeleton for **6** \[[@B19-marinedrugs-15-00120]\]. The ^1^H-^1^H COSY correlations from H-2 to NH, H~2~-1 and H-3, and the HMBC correlations from NH to C-1′, from H~2~-2′ to C-1′ and C-3′, and from H-3 to C-1 and C-2 confirmed the sphingosine skeleton. That the two double bonds were placed on C-4 and C-8 was supported by ^1^H-^1^H COSY correlations of H-3/H-4, H-4/H-5, H-5/H~2~-6, H~2~-6/H~2~-7, H~2~-7/H-8, H-8/H-9 and H-9/H~2~-10, as well as by HMBC correlations from H-3 to C-4 and C-5, from H-8 to C-6 and C-7, and from H~2~-10 to C-8 and C-9 ([Figure 5](#marinedrugs-15-00120-f005){ref-type="fig"}A). That the sphingoid long chain base (LCB) and the long chain fatty acid base (FAB) of the amide portion contained 18 and 14 carbons, respectively, was evidenced by the electrospray ionization mass spectroscopy (ESI-MS) fragments at *m/z* 219, 228, 262, 283, 394 ([Figure 5](#marinedrugs-15-00120-f005){ref-type="fig"}B) \[[@B20-marinedrugs-15-00120]\]. The number of the carbon for the FAB was further validated through electron impact mass spectrometry (EI-MS) molecular ion at *m/z* 242 \[M\]^+^ for the methyl tetradecanoate obtained after methanolysis of **6** with 5% HCl-MeOH. Therefore, the planar structure and the key connectivities of **6** were established.

That the geometry of C-4/C-5 and C-8/C-9 double bonds are *trans* was based on the vicinal coupling constants *J*~4,5~ = 15.4 Hz and *J*~8,9~ = 15.2 Hz, as well as the chemical shifts of C-6 (δ~C~ 32.3) and C-7 (δ~C~ 32.1) \[[@B21-marinedrugs-15-00120]\]. The absolute stereochemistry of **6** was determined as [d]{.smallcaps}-(*−*)-*erythro*-2*S*,3*R* configuration based on the chemical shifts of C-2 (δ~C~ 54.5) and C-3 (δ~C~ 74.7), which were in good agreement with those reported for *N*-palmitoyl-[d]{.smallcaps}-*erythro*-(2*S*,3*R*)-octadecasphinga-4(*E*)-en (C-2 for 54.5 and C-3 for 74.7) \[[@B22-marinedrugs-15-00120],[@B23-marinedrugs-15-00120]\]. Based on the above analyses, the structure of **6** was determined as (2*S*,3*R*,4*E*,8*E*)-2-(tetradecanoylamino)-4,8-octadecadien-l,3-diol.

The molecular formula of compound **7** was assigned as C~32~H~61~NO~4~ on the basis of (+)-HRESIMS pseudomolecular ion peak at *m/z* 546.4496 \[M\]^+^ (calcd. for C~32~H~61~NO~4~Na, 546.4498) and the ^1^H- and ^13^C-NMR spectra ([Table 2](#marinedrugs-15-00120-t002){ref-type="table"}). The ^13^C-NMR spectrum of **7** showed a close resemblance to that of **6**, except for the additional hydroxyl group on C-2′ in the FAB, since **7** showed different chemical shifts of C-1′ (δ~C~ 175.0), C-2′ (δ~C~ 72.4) and C-3′ (δ~C~ 34.8) in its FAB. HMBC correlations of H-2′ (δ~H~ 4.12) to C-1′ and C-3′ confirmed that the hydroxyl group was on C-2′ ([Figure 6](#marinedrugs-15-00120-f006){ref-type="fig"}A). A series of fragment ions at *m/z* 227, 242, 283 and 296 in the (‒)-ESIMS spectrum ([Figure 6](#marinedrugs-15-00120-f006){ref-type="fig"}B), deduced the lengths of LCB and FAB to be 18 and 14 carbons, respectively. Additionally, the length of FAB was further validated through (+)-EIMS molecular ion at *m/z* 258 \[M\]^+^ of (*R*)-methyl 2-hydroxytetradecanoate obtained from methanolysis of **7**. Comparisons of the optical rotation of **7** ($\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{22}$ +9.5°) with (2*S*,3*R*,2′*R*,4*E*)-2′-hydroxy-C16-ceramide (\[α\]~D~ +5.2°) and its 2′*S*-isomer (\[α\]~D~ −16.1°), suggested that **7** and (2*S*,3*R*,2′*R*,4*E*)-2′-hydroxy-C16-ceramide have the same absolute configurations for core chiral centers C-2, C-3 and C-2′ \[[@B24-marinedrugs-15-00120]\]. Thus, compound **7** was determined as (2*S*,3*R*,2′*R*,4*E*,8*E*)-2-(tetradecanoylamino)-4,8-octadecadien-l,3,2′-triol.

Compounds **1**--**9** were evaluated for their cytotoxicity against human myeloid leukemia cell line HL-60, human hepatocellular carcinoma HepG-2, and human gastric carcinoma SGC-7901 using an MTT assay, and results are shown in [Table 3](#marinedrugs-15-00120-t003){ref-type="table"}. Compound **1** displayed a moderate cytotoxicity to the test cell lines with IC~50~ values between 12.34 μM and 18.37 μM, while **2**--**4** did not show any cytotoxicity. Since **5** exhibited strong cytotoxicity against the test tumor cell lines with IC~50~ values between 4.12 μM and 7.32 μM, it can be considered as a potential for the further development of an anticancer agent. Compounds **6**--**9** showed weak cytotoxicity against all the test tumor cell lines with IC~50~ values ranging from 21.13 μM to 58.15 μM; however, they showed stronger cytotoxicity against HepG-2 and SGC-7901 than HL-60, suggesting a selectivity of these ceramides against HepG-2 and SGC-7901. Furthermore, ceramide **7,** having the 2′-OH group in its FAB, displayed stronger cytotoxicity than its dehydroxy counterparts, indicating that the 2′-OH group in the FAB may play an important role in the expression of cytotoxicity for ceramides \[[@B24-marinedrugs-15-00120],[@B25-marinedrugs-15-00120]\].

3. Experimental Section {#sec3-marinedrugs-15-00120}
=======================

3.1. General Experimental Procedures {#sec3dot1-marinedrugs-15-00120}
------------------------------------

Optical rotations were measured on a Perkin-Elmer 343 polarimeter. 1D and 2D NMR spectra were obtained in CDCl~3~ or CD~3~OD on a Bruker AVANCE-500 spectrometer, with tetramethylsilane (TMS) as an internal standard. Chemical shifts (δ) were expressed in ppm and coupling constants in Hz. EI-MS spectrum was obtained on a Finnigan MAT 212 mass spectrometer. ESI-MS and HR-ESI-MS spectra were taken on a Micromass Quattro mass spectrometer (Micromass, Manchester, UK). CD spectrum was recorded on JASCOJ-720 spectrophotometer (JASCO Corporation, Tokyo, Japan). Separation and purification were performed by CC on silica gel H (10--40 μm, Qingdao Marine Chemical Inc., Qingdao, China), Sephadex LH-20 (Pharmacia Inc., New Jersey, NJ, USA) and reversed-phase Si gel (Lichroprep RP-18, 40--63 μm, Merck Inc., Darmstadt, Germany). Semi-preparative HPLC was carried out on a Dionex P680 liquid chromatograph equipped with a UV 170 UV/Vis detector at 206 nm using a YMC-Pack R&D ODS-A column (250 mm × 20 mm i.d., 5 μm, YMC, Kyoto, Japan). Compounds detection in the thin-layer chromatography (TLC) plate was achieved by spraying the silica gel plates (Qingdao Marine Chemical Inc., Qingdao, China) with 15% H~2~SO~4~ in ethanol followed by heating.

3.2. Animal Material {#sec3dot2-marinedrugs-15-00120}
--------------------

The marine bryozoan *Cryptosula pallasiana* was collected in March 2009 from Huang Island, Qingdao City, Shandong Province of China, was identified by one of us (H.-W. Lin). A voucher specimen (No: QD-0903-1) was deposited in Marine Laboratory, Changzheng Hospital, Second Military Medical University.

3.3. Extraction and Isolation {#sec3dot3-marinedrugs-15-00120}
-----------------------------

The fresh animal *C. pallasiana* (about 20 kg) was exhaustively extracted with 95% EtOH at room temperature. Followed the extraction procedure we described previously, CCl~4~ fraction (about 12.9 g) was further separated by CC on Sephadex LH-20 with CHCl~3~/MeOH (1:1) as an eluting solvent to afford three fractions (Frs. A--C) \[[@B5-marinedrugs-15-00120]\]. Fr. A (5.56 g) was subjected to a reversed-phase silica gel column eluting with a mixture of MeOH/H~2~O (4:1) and MeOH to afford Fr. A~1~ and Fr. A~2~, respectively. Fr. A~2~ was submitted to a silica gel column and eluted with petroleum ether/EtOAc (15:1, 10:1, 5:1, 1:1) to give 12 fractions (Frs. A~2~-1--A~2~-12). The isolation of 16 alkaloids, 13 sterols, three aromatic compounds and two glycerol derivatives from Fr. B, Fr. C, and Fr. A~2~-4 to Fr. A~2~-9 have been reported previously \[[@B4-marinedrugs-15-00120],[@B5-marinedrugs-15-00120],[@B6-marinedrugs-15-00120]\]. Fr. A~2~-3 (183.0 mg) was purified by semi-preparative HPLC to give **1** (2.5 mg, *t*~R~ = 67.2 min) and **2** (20.9 mg, *t*~R~ = 73.4 min), using MeOH/H~2~O (19:1) as mobile phase at a flow rate of 8.0 mL/min. Fr. A~2~-11 (114.7 mg) was purified by semi-preparative HPLC to obtain **3** (6.2 mg, *t*~R~ = 47.7 min) and **4** (20.9 mg, *t*~R~ = 54.4 min), using MeOH/H~2~O (9:1) as mobile phase at a flow rate of 8.0 mL/min. Fr. A~1~ (2.4 g) was eluted with CHCl~3~/MeOH (1:1) on Sephadex LH-20, and then further purified by semi-preparative HPLC to give **5** (4.0 mg, *t*~R~ = 39.6 min), using MeOH/H~2~O (1:3) as mobile phase at a flow rate of 8.0 mL/min. Fr. A~2~-10 (150.0 mg) was eluted with CHCl~3~/MeOH (1:1) on Sephadex LH-20, and then further purified by semi-preparative HPLC to afford **6** (9.3 mg, *t*~R~ = 49.5 min), **7** (7.4 mg, *t*~R~ = 46.3 min), **8** (8.5 mg, *t*~R~ = 51.4 min) and **9** (7.1 mg, *t*~R~ = 54.7 min), using MeOH/H~2~O (19:1) as mobile phase at a flow rate of 8.0 mL/min.

### 3.3.1. (23*R*)-Methoxycholest-5,24-dien-3β-ol (**1**) {#sec3dot3dot1-marinedrugs-15-00120}

White amorphous powder, $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{22}$ −22.0° (*c* 0.05, CHCl~3~); ^1^H- and ^13^C-NMR data see [Table 1](#marinedrugs-15-00120-t001){ref-type="table"}; (+)-ESI-MS *m/z*: 437 \[M + Na\]^+^, 415 \[M + H\]^+^, 385, 349, 318, 274, 256; (+)-HRESIMS *m/z*: 437.3395 \[M + Na\]^+^ (calcd. for C~28~H~46~O~2~Na, 437.3396).

### 3.3.2. (2*S*,3*R*,4*E*,8*E*)-2-(Tetradecanoylamino)-4,8-octadecadien-l,3-diol (**6**) {#sec3dot3dot2-marinedrugs-15-00120}

White amorphous powder, $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{22}$ −5.7° (*c* 0.10, CHCl~3~); ^1^H- and ^13^C-NMR data see [Table 2](#marinedrugs-15-00120-t002){ref-type="table"}; (+)-ESIMS *m/z*: 530 \[M + Na\]^+^, 437, 330, 302, 274, 262, 256, 228, 219; (‒)-ESIMS *m/z*: 552 \[M + COOH\]^−^, 542 \[M + Cl\]^−^, 506 \[M − H\]^−^, 447, 394, 341, 283, 255, 218, 186, 143, 126; (+)-HRESIMS *m/z*: 530.4545 \[M + Na\]^+^ (calcd. for C~32~H~61~NO~3~Na, 530.4549).

### 3.3.3. (2*S*,3*R*,2′*R*,4*E*,8*E*)-2-(Tetradecanoylamino)-4,8-octadecadien-l,3,2′-triol (**7**) {#sec3dot3dot3-marinedrugs-15-00120}

White amorphous powder, $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{22}$ +9.5° (*c* 0.10, CHCl~3~); ^1^H- and ^13^C-NMR data see [Table 2](#marinedrugs-15-00120-t002){ref-type="table"}; (+)-ESIMS *m/z*: 546 \[M + Na\]^+^, 437, 330, 274, 262, 256; (‒)-ESIMS *m/z*: 558 \[M + Cl\]^−^, 522 \[M − H\]^−^, 340, 296, 283, 242, 227; (+)-HRESIMS *m/z*: 546.4496 \[M + Na\]^+^ (calcd. for C~32~H~61~NO~4~Na, 546.4498).

3.4. Methanolysis of Compounds ***6*** and ***7*** {#sec3dot4-marinedrugs-15-00120}
--------------------------------------------------

Compounds **6** and **7** (each about 3 mg) were dissolved in 5% HCl-MeOH (3 mL), respectively, and then refluxed for 12 h at 80 °C. The reaction mixture was extracted with *n*-hexane (3 × 4 mL). The *n*-hexane portion was washed with H~2~O and concentrated in vacuo to yield methyl tetradecanoate and (*R*)-methyl 2-hydroxytetradecanoate, respectively. The H~2~O portion was neutralized with NH~4~OH, and then further concentrated in vacuo to yield the corresponding LCB with specific rotation $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{22}$ at −3.4° (c 0.05, CHCl~3~).

Methyl tetradecanoate: EI-MS *m/z* 242 \[M\]^+^ (25), 211 \[M − CH~3~\]^+^ (11), 199 \[M − COCH~3~\]^+^ (22), 185 (8), 171 (4), 157 (7), 143 (22), 129 (9), 115 (4), 101 (9), 87 (61), 74 (100), 55 (24).

(*R*)-Methyl 2-hydroxytetradecanoate: $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{22}$ −6.5° (*c* 0.05, CHCl~3~); EI-MS *m/z* 258 \[M\]^+^ (7), 199 \[M − COCH~3~\]^+^ (65), 125 (30), 111 (56), 90 (47), 83 (85), 69 (100), 55 (92).

3.5. MTT Cytotoxicity Assays {#sec3dot5-marinedrugs-15-00120}
----------------------------

Compounds **1**--**9** were evaluated for their cytotoxic activity against human tumor cell lines HL-60, HepG-2 and SGC-7901 using MTT assay. The cell lines were obtained from American type culture collection (ATCC), and were seeded to RPMI-1640 medium with 10% fetal bovine serum and 100 U/mL benzyl penicillin-streptomycin solutions, at 37 °C in a humidified atmosphere with 5% CO~2~/air for 24 h. Then the test samples were added and incubated at 37 °C for another 72 h. The detailed procedure for MTT assay can be found in our previous published literature \[[@B5-marinedrugs-15-00120]\]. The cytotoxic activity was expressed as IC~50~ value using adriamycin as a positive control.

4. Conclusions {#sec4-marinedrugs-15-00120}
==============

A new sterol (**1**), two new ceramides (**6**,**7**) and six known compounds (**2**--**5**,**8**,**9**) were identified from the marine bryozoan *C. pallasiana*. Among the isolated compounds, sterol **1** showed novelty in the C-23*R* methoxy group and double bond between C-24 and C-25 in its side chain. Since this is the first report of ceramides in this species, it can be considered important for its chemotaxonomic significance. Furthermore, ceramides with 14 carbons in the FAB were different from those we previously obtained from *Bugula neritina* \[[@B25-marinedrugs-15-00120],[@B26-marinedrugs-15-00120]\]. All compounds were evaluated for their cytotoxicity, and lactone (**5**) was found to exhibit stronger cytotoxicity than sterols and ceramides, suggesting that it could be responsible for the cytotoxicity of *C. pallasiana*.
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###### 

^1^H- and ^13^C-NMR (500 and 125 MHz, CDCl~3~) data of **1** ^a^.

  No.   δ~C~    δ~H~ mult., *J* in Hz   No.         δ~C~    δ~H~ mult., *J* in Hz
  ----- ------- ----------------------- ----------- ------- --------------------------
  1     37.3    α 1.86, m               13          42.5    --
                β 1.08, m               14          56.9    1.04, m
  2     31.7    α 1.84, m               15          24.3    α 1.57, m
                β 1.50, m                                   β 1.07, m
  3     71.8    3.52, m                 16          28.2    α 1.83, m
  4     42.3    α 2.28, m                                   β 1.30, m
                β 2.23, m               17          56.8    1.01, m
  5     140.7   --                      18          12.0    0.73, s
  6     121.7   5.35, t (2.5)           19          19.4    1.00, s
  7     31.9    α 1.50, m               20          32.5    1.66, m
                β 1.97, m               21          18.7    0.95, d (5.9)
  8     31.9    1.50, m                 22          42.5    α 0.92, m
                                                            β 1.68, m
  9     50.1    0.93, m                 23          74.8    3.94, dt (9.3, 3.1)
  10    36.5    --                      24          127.0   5.03, td (9.0, 2.6, 1.3)
  11    21.1    α 1.43, m               25          134.5   --
                β 1.49, m               26          18.2    1.67, d (1.0)
  12    39.8    α 1.16, m               27          25.9    1.74, d (1.1)
                β 2.03, m               23-OCH~3~   55.7    3.21, s

^a^ Assignments based on DEPTs and HSQC.
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###### 

^1^H- and ^13^C-NMR (500 and 125 MHz, CDCl~3~) of **6** and **7** ^a^.

  No.       6            7                                   
  --------- ------------ ---------------------- ------------ ----------------------
  1         62.5         3.70, dd (11.3, 3.3)   62.2         3.72, dd (11.0, 3.0)
                         3.90, m                             3.89, m
  2         54.5         3.95, dd (11.3, 3.5)   54.4         3.92, br d (11.0)
  3         74.7         4.32, m                74.7         4.30, m
  4         129.2        5.54, dd (15.4, 6.4)   129.2        5.52, dd (15.5, 6.0)
  5         133.6        5.78, dt (15.4, 6.6)   133.5        5.75, dt (15.5, 6.1)
  6         32.3         1.97, q (6.7)          32.4         1.96, q (6.5)
  7         32.1         2.12, m                32.2         2.11, m
  8         131.4        5.42, dt (15.2, 6.3)   131.3        5.41, m
  9         129.0        5.37, dt (15.2, 6.4)   129.0        5.38, m
  10        32.6         2.08, m                32.2         2.07, m
  11\~15    29.2--29.7   1.26, br s             29.2--29.7   1.26, br s
  16        31.9         1.26, br s             32.0         1.26, br s
  17        22.7         1.26, br s             22.7         1.26, br s
  18        14.1         0.88, t (6.8)          14.1         0.87, t (7.0)
  1′        174.0        --                     175.0        --
  2′        36.9         2.23, t (7.5)          72.4         4.12, dd (7.8, 3.4)
  3′        25.8         1.64, m                34.8         2.16, t (3.3)
  4′        29.2--29.7   1.26, br s             31.8         1.26, br s
  5′        29.2--29.7   1.26, br s             25.1         1.63, m
  6′\~11′   29.2--29.7   1.26, br s             29.2--29.7   1.26, br s
  12′       31.9         1.26, br s             31.9         1.26, br s
  13′       22.7         1.26, br s             22.7         1.26, br s
  14′       14.1         0.88, t (6.8)          14.1         0.87, t (7.0)
  NH        --           6.25, d (7.5)          --           6.20, d (7.8)

^a^ Assignments based on DEPTs and HSQC.
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###### 

Cytotoxicity of compounds **1**--**9** against HL-60, HepG2 and SGC7901 tumor cell lines in vitro (IC~50~, μM) **^a^**.

  Compound         HL-60          HepG-2         SGC-7901
  ---------------- -------------- -------------- --------------
  1                17.64 ± 0.32   12.34 ± 0.12   18.37 ± 0.17
  2                \>100          \>100          \>100
  3                \>100          \>100          \>100
  4                \>100          \>100          \>100
  5                6.29 ± 0.11    4.12 ± 0.15    7.32 ± 0.26
  6                32.26 ± 0.23   26.69 ± 0.21   27.14 ± 0.30
  7                25.32 ± 0.17   21.13 ± 0.13   22.74 ± 0.16
  8                35.72 ± 0.36   28.53 ± 0.24   30.31 ± 0.14
  9                58.15 ± 0.28   46.21 ± 0.17   45.79 ± 0.12
  Adriamycin ^b^   2.51 ± 0.14    2.73 ± 0.23    2.65 ± 0.17

^a^ IC~50~ values are means from three independent experiments in which each compound concentration was tested in three replicate wells; ^b^ Adriamycin as a positive control.

[^1]: These authors contributed equally to this work.
